Emory University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).

1,208 total trials 208 currently recruiting 767 completed early-phase tilt top decile by trial count

Emory University: 1,208 sponsored US clinical trials, 208 recruiting.

Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.

Top-decile sponsor footprint

Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,208 total, page 10 of 25

COMPLETED Phase 4

Pre-oxygenation With Real Time End-tidal Oxygen Measurements Versus Single Breath Measurements

NCT03840486

COMPLETED NA

UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)

NCT04075656

COMPLETED Phase 2

Trikafta in Cystic Fibrosis Patients

NCT03506061

COMPLETED Phase 2

Clarithromycin Mechanisms in Hypersomnia Syndromes

NCT04026958

COMPLETED NA

Lipid Challenge in Adults

NCT03948295

COMPLETED NA

Compassion-Centered Spiritual Health for Faculty and Staff

NCT04060901

TERMINATED NA

Feasibility of EnChroma Use in the Emergency Department Setting

NCT04021914

COMPLETED Phase 3

In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)

NCT03932240

COMPLETED NA

Carepartner Collaborative Integrated Therapy in Sub-Acute Stroke

NCT04040751

COMPLETED NA

Endoscopic vs. Suction Device Calibration in Sleeve Gastrectomy

NCT03939819

COMPLETED NA

Emory Teaching Kitchen Collaborative

NCT04005495

COMPLETED Phase 2

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

NCT02757885

COMPLETED NA

Dexcom G6 Intervention Study

NCT03877068

COMPLETED NA

Adolescent Idiopathic Scoliosis (AIS) Gold Standard for Blood Loss

NCT03990376

COMPLETED NA

Neuroplastic Mechanisms Underlying Augmented Neuromuscular Training

NCT04069520

COMPLETED NA

Electronic Pre-exposure Prophylaxis (PrEP) Initiation and Maintenance Home Care System

NCT03729570

TERMINATED Phase 4

Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone

NCT03704584

COMPLETED NA

Structured Function-Based Elopement Treatment Program

NCT03899831

COMPLETED NA

Dementia-Friendly Faith Villages to Support African American Families

NCT04983693

COMPLETED NA

Ultrasound in Diagnosing Patients With Skin Lesions

NCT03914846

COMPLETED NA

Pre-exposure Prophylaxis (PrEP) at Home

NCT03569813

COMPLETED Phase 2

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

NCT03910387

COMPLETED NA

Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer

NCT03819088

COMPLETED Phase 2

Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia

NCT03772314

COMPLETED Phase 3

Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)

NCT03818737

COMPLETED NA

Determining the Benefits of Improving Communication in BPAP/CPAP Users

NCT03795753

COMPLETED Phase 1

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

NCT03976752

TERMINATED Phase 4

Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

NCT03743025

COMPLETED NA

Developing a Lifestyle Intervention for South Asians

NCT03861546

COMPLETED NA

Dexcom G6 Observational Study

NCT03832907

COMPLETED NA

Syngery-Evaluating the Impact of Decision Aid

NCT03832868

COMPLETED Phase 2

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

NCT03691493

COMPLETED NA

Reducing Disparities in Living Donor Transplant Among African Americans

NCT03819686

TERMINATED Phase 2

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

NCT03506048

COMPLETED Phase 2

Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

NCT03800602

COMPLETED Phase 3

IDegLira HIGH Trial

NCT03737240

COMPLETED NA

Universal Screening for Vocal Fold Motion Impairment in Children Undergoing Congenital Cardiac Surgery

NCT03882450

COMPLETED NA

Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors

NCT03539835

COMPLETED

Contraceptive Hormones, Immunity, and Microbiome Evaluation

NCT03660046

TERMINATED NA

Cognitive Behavioral Therapy for African Americans With Uncontrolled Type-2 Diabetes

NCT03562767

COMPLETED NA

Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases

NCT03680144

COMPLETED Phase 1

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT03739619

COMPLETED NA

Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials

NCT03543878

COMPLETED NA

THRIVE Breast Cancer App Study

NCT03592771

TERMINATED NA

Acceptability, Feasibility and Safety of a Yoga Program for Chronic Pain in Sickle Cell Disease

NCT03694548

COMPLETED NA

Trial to Improve Multisensory Neural Processing, Language & Motor Outcomes in Preterm Infants

NCT03232931

COMPLETED Phase 1

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

NCT03605719

TERMINATED Phase 4

The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics

NCT03686514

COMPLETED Phase 4

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

NCT03701061

COMPLETED Phase 2

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

NCT03579771

← Previous Page 10 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 154
Phase 2 190
Phase 3 36
Phase 4 134

What is open in the Emory University pipeline

208 recruiting of 1,208 indexed (17% open); 767 completed (63%).

Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top condition: Depression (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Emory University: open-pipeline peers nationwide

Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Emory UniversityNorthwestern UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBaylor Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Hunter College of City University of New YorkOchsner Health System
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,208 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Emory University page

1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.

  • 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.